Trial · NCT00414973
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women | Teriparatide - Females | 6.04 | Standard Error 0.48 | percentage change in lumbar spine BMD | |
| Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Postmenopausal Women | Calcitonin - Females | 1.65 | Standard Error 0.65 | percentage change in lumbar spine BMD | |
| Percentage Change From Baseline to 24 Week Endpoint in Total Hip Bone Mineral Density (BMD), Postmenopausal Women | Teriparatide - Females | -0.53 | Standard Error 0.44 | percentage change in total hip BMD | |
| Percentage Change From Baseline to 24 Week Endpoint in Total Hip Bone Mineral Density (BMD), Postmenopausal Women | Calcitonin - Females | -0.62 | Standard Error 0.59 | percentage change in total hip BMD | |
| Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Postmenopausal Women | Teriparatide - Females | Week 12 Percentage Change (n=202, n=102) | 113.87 | Inter-Quartile Range 21.46 | percentage change in osteocalcin |
| Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Postmenopausal Women | Calcitonin - Females | Week 12 Percentage Change (n=202, n=102) | -7.67 | Inter-Quartile Range 5.43 | percentage change in osteocalcin |
| Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Postmenopausal Women | Teriparatide - Females | Week 24 Percentage Change (n=191, n=97) | 137.45 | Inter-Quartile Range 36.53 | percentage change in osteocalcin |
| Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Postmenopausal Women | Calcitonin - Females | Week 24 Percentage Change (n=191, n=97) | -10.58 | Inter-Quartile Range 8.21 | percentage change in osteocalcin |
| Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Men | Teriparatide - Males | 6.01 | Standard Error 1.20 | percentage change in lumbar spine BMD | |
| Percentage Change From Baseline to 24 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD), Men | Calcitonin - Males | 3.38 | Standard Error 1.77 | percentage change in lumbar spine BMD | |
| Percentage Change From Baseline to 24 Week Endpoint in Total Hip Bone Mineral Density (BMD), Men | Teriparatide - Males | 0.37 | Standard Error 1.11 | percentage change in total hip BMD | |
| Percentage Change From Baseline to 24 Week Endpoint in Total Hip Bone Mineral Density (BMD), Men | Calcitonin - Males | 1.34 | Standard Error 1.54 | percentage change in total hip BMD | |
| Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Men | Teriparatide - Males | Week 12 Percentage Change (n=21, n=11) | 107.27 | Inter-Quartile Range 14.88 | percentage change in osteocalcin |
| Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Men | Calcitonin - Males | Week 12 Percentage Change (n=21, n=11) | 4.35 | Inter-Quartile Range 13.48 | percentage change in osteocalcin |
| Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Men | Teriparatide - Males | Week 24 Percentage Change (n=21, n=11) | 79.26 | Inter-Quartile Range 26.94 | percentage change in osteocalcin |
| Percentage Change From Baseline to 12 Weeks and 24 Weeks in Osteocalcin, Men | Calcitonin - Males | Week 24 Percentage Change (n=21, n=11) | -17.65 | Inter-Quartile Range 5.21 | percentage change in osteocalcin |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00414973/results